William Langston

Q: What Schools Are Affiliated With William Langston

William Langston is affiliated with the following schools: University of Missouri, Stanford University, Massachusetts Institute of Technology

William Langston's AcademicInfluence.com Rankings

William Langston

Medical

#157

World Rank

#242

Historical Rank

Neurology

#41

World Rank

#77

Historical Rank

medical Degrees

Download Badge

Medical

Why Is William Langston Influential?

(Suggest an Edit or Addition)

According to Wikipedia, J. William Langston is the founder and chief scientific officer, movement disorder specialist, and chief executive officer of the Parkinson's Institute and Clinical Center in Sunnyvale, California, the founding member of the Scientific Advisory Board for the Michael J. Fox Foundation and the Co-Editor-in-Chief of the Journal of Parkinson's Disease. He is a graduate of the University of Missouri School of Medicine. Langston was formerly a faculty member at Stanford University and Chairman of Neurology at Santa Clara Valley Medical Center in San Jose, California. Langston has authored or co-authored some 360 peer-reviewed articles in the field of neurology, most of which are on Parkinson's disease and related disorders. Langston gained national and international recognition in 1982 for the discovery of the link between a "synthetic heroin" contaminant and parkinsonism.

(See a Problem?)

William Langston's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. (1983) (4780)
Rotenone, Paraquat, and Parkinson’s Disease (2011) (1123)
Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure (1999) (985)
Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey (1984) (950)
Parkinson disease in twins: an etiologic study. (1999) (936)
Effect of deprenyl on the progression of disability in early Parkinson's disease. (1989) (886)
Environmental Risk Factors and Parkinson's Disease: Selective Degeneration of Nigral Dopaminergic Neurons Caused by the Herbicide Paraquat (2002) (788)
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. (1989) (619)
Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) (1985) (581)
Pargyline prevents MPTP-induced parkinsonism in primates. (1984) (566)
The parkinson's complex: Parkinsonism is just the tip of the iceberg (2006) (561)
The Neurobehavioral Cognitive Status Examination: a brief but quantitative approach to cognitive assessment. (1987) (542)
Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (1992) (506)
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy (2017) (502)
Lewy bodies and parkinsonism in families with parkin mutations (2001) (488)
Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease (2011) (482)
AETIOLOGY OF PARKINSON'S DISEASE (1983) (477)
1-Methyl-4-phenylpyridinium ion (MPP+): Identification of a metabolite of MPTP, a toxin selective to the substantia nigra (1984) (420)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours (2017) (408)
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication (2007) (401)
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys (1986) (374)
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. (2004) (371)
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa (1996) (356)
Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease (1985) (326)
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. (2002) (325)
(+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. (1988) (296)
Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. (1983) (269)
SNCA Triplication Parkinson's Patient's iPSC-derived DA Neurons Accumulate α-Synuclein and Are Susceptible to Oxidative Stress (2011) (268)
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects. (1984) (267)
Head injury and Parkinson's disease risk in twins (2006) (264)
Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration (1988) (254)
Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial (2002) (251)
MPTP: current concepts and controversies. (1986) (249)
When DLB, PD, and PSP masquerade as MSA (2015) (247)
The MPTP Story (2017) (245)
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. (2015) (243)
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: Reversal by gene correction (2014) (240)
Rapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain (1991) (239)
Genomic investigation of α‐synuclein multiplication and parkinsonism (2008) (231)
Do environmental toxins cause Parkinson's disease? A critical review (1990) (226)
Occupation and risk of parkinsonism: a multicenter case-control study. (2009) (225)
The hypothalamus in parkinson disease (1978) (220)
Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. (1993) (219)
The correlation between phase shifts in gradient-echo MR images and regional brain iron concentration. (1999) (214)
Low-grade astrocytoma: a decade of experience at St. Jude Children's Research Hospital. (1997) (213)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes (2011) (207)
The role of radiotracer imaging in Parkinson disease (2005) (205)
Granulocytic sarcoma in childhood leukemia: imaging features. (1994) (193)
Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra (1987) (192)
Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment (1986) (184)
High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. (1991) (177)
Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization (2000) (177)
The etiology of Parkinson's disease with emphasis on the MPTP story (1996) (173)
Smoking and Parkinson’s disease in twins (2002) (172)
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. (2009) (167)
Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity? (1985) (166)
Intellectual changes in patients with MPTP‐induced parkinsonism (1985) (166)
Chapter 36: Astrocytes and Parkinson's disease (1992) (163)
Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. (1980) (160)
The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease (1990) (160)
Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions (1994) (157)
Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1992) (152)
Cognitive change following MPTP exposure (1990) (152)
Oxidation reactions in Parkinson's disease. Discussion (1990) (150)
Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations (1993) (146)
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers (2011) (146)
Solvent exposures and parkinson disease risk in twins (2012) (139)
Rapid ATP Loss Caused by Methamphetamine in the Mouse Striatum: Relationship Between Energy Impairment and Dopaminergic Neurotoxicity (1994) (138)
Subtle white matter volume differences in children treated for medulloblastoma with conventional or reduced dose craniospinal irradiation. (2000) (138)
White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. (2004) (132)
Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. (1990) (131)
Increased striatal dopamine turnover following acute administration of rotenone to mice (2000) (130)
Aging and the nigrostriatal dopamine system: a non-human primate study. (1994) (129)
Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. (1996) (128)
Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates (2006) (128)
MPTP and parkinson's disease (1985) (127)
Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. (1996) (127)
Aminergic Metabolites in Cerebrospinal Fluid of Humans Previously Exposed to MDMA: Preliminary Observations a (1990) (122)
MPTP neurotoxicity: an overview and characterization of phases of toxicity. (1985) (121)
Atypical white matter volume development in children following craniospinal irradiation. (2005) (121)
Survival and functional outcome of children with hypothalamic/chiasmatic tumors (2003) (118)
Abnormalities of the central nervous system in very young children with sickle cell anemia. (1998) (116)
Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum (1985) (115)
Lack of nigrostriatal pathology in a rat model of proteasome inhibition (2006) (109)
Parkinson's disease: current and future challenges. (2002) (108)
Postural instability in Parkinson’s disease: the adrenergic hypothesis and the locus coeruleus (2009) (107)
Lack of major olfactory dysfunction in MPTP‐induced parkinsonism (1992) (106)
Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. (1999) (105)
Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. (2005) (104)
Low-grade astrocytoma with neuraxis dissemination at diagnosis. (1995) (104)
Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. (2000) (104)
Epidemiology versus genetics in parkinson's disease: Progress in resolving an age‐old debate (1998) (103)
Astrocytes and Parkinson's disease. (1992) (103)
Subtle brain abnormalities in children with sickle cell disease: Relationship to blood hematocrit (1999) (99)
The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment (1992) (97)
Investigating levodopa-induced dyskinesias in the parkinsonian primate. (2000) (97)
Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter (2007) (97)
Preirradiation cisplatin and etoposide in the treatment of high-risk medulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. (1990) (96)
Benign epileptiform transients of sleep (1977) (96)
Essential tremor in twins (2001) (95)
Failure to find the a‐synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease (1998) (94)
Pleomorphic xanthoastrocytoma: favorable outcome after complete surgical resection. (2001) (93)
Aetiology of Parkinsońs disease (1983) (93)
An electron microscopic study of MPTP-induced inclusion bodies in an old monkey (1988) (92)
Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism (2000) (91)
Effects of 1‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine and 1 ‐Methyl‐4‐Phenylpyridinium Ion on ATP Levels of Mouse Brain Synaptosomes (1990) (91)
Occupation and parkinsonism in three movement disorders clinics (2005) (90)
A hybrid neural network analysis of subtle brain volume differences in children surviving brain tumors. (1998) (90)
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. (2004) (89)
Increased vulnerability of dopaminergic neurons in MPTP‐lesioned interleukin‐6 deficient mice (2002) (87)
5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates (1988) (87)
Prospective evaluation of the brain in asymptomatic children with neurofibromatosis type 1: relationship of macrocephaly to T1 relaxation changes and structural brain abnormalities. (2001) (86)
Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease (2010) (85)
Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease (2013) (85)
GDNF Induces a Dystonia-like State in Neonatal Rats and Stimulates Dopamine and Serotonin Synthesis (1996) (84)
Head injury, alpha‐synuclein Rep1, and Parkinson's disease (2012) (83)
Diffusion tensor imaging of tract involvement in children with pontine tumors. (2006) (83)
Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits (2012) (82)
Absence of mutations in the coding region of the α-synuclein gene in pathologically proven Parkinson's disease (1998) (81)
Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection (1993) (79)
Cerebral infarction secondary to sickle cell disease: arteriographic findings. (1980) (78)
Stem cells for Parkinson disease and ALS: replacement or protection? (2004) (78)
Chronic Oral Nicotine Normalizes Dopaminergic Function and Synaptic Plasticity in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Primates (2006) (78)
Neurotoxins, parkinsonism and Parkinson's disease. (1987) (77)
Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of l-DOPA-treated monkeys (1996) (77)
Does a long preclinical period occur in Parkinson's disease? (1991) (76)
Protective glove use and hygiene habits modify the associations of specific pesticides with Parkinson's disease. (2015) (76)
Older dopaminergic neurons do not recover from the effects of MPTP (1987) (75)
Expression of D3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment (2000) (73)
Bithalamic Involvement Predicts Poor Outcome among Children with Thalamic Glial Tumors (1998) (72)
Systems-Based Analyses of Brain Regions Functionally Impacted in Parkinson's Disease Reveals Underlying Causal Mechanisms (2014) (72)
Higher Vulnerability and Stress Sensitivity of Neuronal Precursor Cells Carrying an Alpha-Synuclein Gene Triplication (2014) (70)
Silent lacunar lesions detected by magnetic resonance imaging of children with brain tumors: a late sequela of therapy. (2000) (70)
Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration (2006) (70)
Can cellular models revolutionize drug discovery in Parkinson's disease? (2009) (69)
Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations (1993) (68)
Essential tremor in twins: An assessment of genetic vs environmental determinants of etiology (2001) (68)
Saccade responses to dopamine in human MPTP‐induced parkinsonism (1986) (68)
The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey (1990) (68)
Permanent neurological deficits due to lithium toxicity (1983) (67)
Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007 (2008) (67)
Primary malignant rhabdoid tumor of the brain: clinical, imaging, and pathologic findings. (1993) (66)
Quantitative MRI of the brain in children with sickle cell disease reveals abnormalities unseen by conventional MRI (1998) (65)
Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson’s disease: an anatomical study (2009) (65)
MPTP‐induced parkinsonism as a model for Parkinson's disease (1989) (65)
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease. (2011) (64)
Small Molecules Greatly Improve Conversion of Human-Induced Pluripotent Stem Cells to the Neuronal Lineage (2012) (61)
Penetrance of LRRK2 G2385R and R1628P is modified by common PD-associated genetic variants. (2012) (59)
LRRK2 dephosphorylation increases its ubiquitination (2015) (59)
Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study. (1998) (58)
Electron microscopy of Lewy bodies in the amygdala-parahippocampal region. Comparison with inclusion bodies in the MPTP-treated squirrel monkey. (1996) (57)
MPTP: insights into the etiology of Parkinson's disease. (1987) (57)
Model fusion: The next phase in developing animal models for parkinson’s disease (2007) (57)
Disulfiram-induced encephalopathy. (1976) (57)
4-Phenylpyridine (4PP) and MPTP: the relationship between striatal MPP+ concentrations and neurotoxicity. (1987) (56)
New amphibian models for the study of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). (1985) (56)
(+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. (1997) (56)
3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain. (1987) (55)
Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. (1995) (54)
Orally administered MDMA causes a long-term depletion of serotonin in rat brain (1988) (53)
Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. (1991) (53)
MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. (1993) (52)
Brain injury in children with sickle cell disease: Prevalence and etiology (2003) (52)
Mechanism of MPTP toxicity: more answers, more questions (1985) (51)
2‐Deoxyglucose Enhances 1‐Methyl‐4‐Phenyl‐1, 2, 3, 6‐Tetrahydropyridine‐Induced ATP Loss in the Mouse Brain (1993) (51)
Mild parkinsonism in persons exposed to 1‐methyl‐4‐phenyl‐1,2,3,6‐ tetrahydropyridine (MPTP) (1989) (51)
Novel α-Synuclein-Immunoreactive Proteins in Brain Samples from the Contursi Kindred, Parkinson's, and Alzheimer's Disease (1998) (50)
VII. The biotransformation of MPTP and disposition of MPP+: Tge effects of aging (1987) (49)
Parkinson’s disease associated with pure ATXN10 repeat expansion (2017) (48)
Enhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys (2005) (47)
The importance of the ‘4–5’ double bond for neurotoxicity in primates of the pyridine derivative MPTP (1984) (47)
Astrocytes as the site for bioactivation of neurotoxins. (1996) (47)
Medulloblastoma with brain stem involvement: the impact of gross total resection on outcome. (1996) (47)
Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration (2018) (46)
The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. (1987) (46)
Iron‐mediated bioactivation of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) in glial cultures (1995) (46)
Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance (2020) (45)
Concordance for Parkinson's disease in twins: A 20‐year update (2019) (45)
Selegiline and mortality in Parkinson's disease (1996) (45)
The influence of hypoxemia and cobalt on erythropoietin production in the isolated perfused dog kidney. (1967) (44)
Decreased α-synuclein expression in the aging mouse substantia nigra (2009) (44)
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases (2017) (44)
Focal signs and brain CT scan in psychiatric patients. (1985) (44)
Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys (2004) (44)
Malignant Evolution of Choroid Plexus Papilloma (1999) (44)
Brain stem involvement in children with neurofibromatosis type 1: role of magnetic resonance imaging and spectroscopy in the distinction from diffuse pontine glioma. (1997) (43)
Multisystem Lewy body disease and the other parkinsonian disorders (2015) (43)
CYP2D6 allelic frequencies in young-onset Parkinson's disease (1996) (43)
Parkinsonism caused by petroleum waste ingestion (1994) (42)
The promise of stem cells in Parkinson disease. (2005) (40)
The native form of α-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls (1998) (40)
Selegiline as neuroprotective therapy in Parkinson's disease: Concepts and controversies (1990) (40)
Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey (2002) (40)
A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation. (2005) (39)
The selective κ-opioid receptor agonist U50,488 reduces l-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates (2007) (39)
EFFECTS OF TESTOSTERONE, COBALT AND HYPOXIA ON ERYTHROPOIETIN PRODUCTION IN THE ISOLATED PERFUSED DOG KIDNEY * (1968) (39)
Ectasia of the basilar artery in children with sickle cell disease: relationship to hematocrit and psychometric measures. (1998) (38)
Novel observations with FDOPA‐PET imaging after early nigrostriatal damage (2001) (38)
The N-methyl-d-aspartate (NMDA) receptor antagonist, dextrorphan, prevents the neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) in rats (1989) (38)
Amphotericin B-induced myelopathy. (1980) (37)
Differential Alterations in Nicotinic Receptor α6 and β3 Subunit messenger RNAs in Monkey Substantia nigra After Nigrostriatal Degeneration (2000) (37)
Impaired glutamate clearance as a consequence of energy failure caused by MPP(+) in astrocytic cultures. (1999) (36)
Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes. (1992) (36)
Proton MR spectroscopy of pediatric brain tumors. (1998) (36)
Current theories on the cause of Parkinson's disease. (1989) (36)
Square‐wave jerks (1977) (35)
BOLD responses to visual stimulation in survivors of childhood cancer (2005) (34)
Hyperviscosity‐induced dementia (1983) (33)
MPTP and aging. Studies in the C57BL/6 mouse. (1993) (33)
Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice. (2000) (33)
Feasibility and efficacy of preirradiation chemotherapy for pediatric brain tumors. (1988) (33)
Chemotherapy for extraocular retinoblastoma. (1994) (33)
Diffuse T1 reduction in gray matter of sickle cell disease patients: evidence of selective vulnerability to damage? (1999) (32)
Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. (2012) (31)
Xeroradiography (1975) (31)
Cyclophosphamide for the treatment of progressive low-grade astrocytoma: a Pediatric Oncology Group phase II Study. (1999) (31)
Tremor in MPTP‐induced parkinsonism (1992) (31)
The biodisposition of MPP+ in mouse brain (1989) (31)
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates (2005) (31)
Effects of angiotensin and renal artery constriction on erythropoietin production. (1967) (31)
Infantile hemifacial spasm. (1976) (31)
Nigrostriatal Reduction of Aromatic L‐Amino Acid Decarboxylase Activity in MPTP‐Treated Squirrel Monkeys: In Vivo and In Vitro Investigations (2000) (30)
GDNF in treatment of Parkinson's disease: response to editorial (2006) (30)
MPTP-induced parkinsonism: an historical case series (2018) (30)
Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson’s Clinic (2018) (30)
Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes. (1992) (30)
Mitochondrial dysfunction in skin fibroblasts from a Parkinson's disease patient with an alpha-synuclein triplication. (2011) (29)
Neuraxis dissemination in pediatric brain tumors. Response to preirradiation chemotherapy (1992) (29)
"Incomplete ring" sign: a simple method for CT detection of spondylolysis. (1985) (29)
Discrete signal processing of dynamic contrast‐enhanced MR imaging: Statistical validation and preliminary clinical application (1994) (29)
7-Nitroindazole prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced ATP loss in the mouse striatum (1999) (29)
Rapid Communication Muscle Mitochondrial ATP Production in Progressive Supranuclear Palsy (1994) (29)
Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. (2000) (28)
Parkin mutations are rare in patients with young-onset parkinsonism in a US population. (2003) (28)
Prospective brain imaging evaluation of children with sickle cell trait: initial observations. (2003) (28)
Postoperative nephrogenic adenoma of bladder. (1976) (27)
Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine (2006) (27)
Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson’s disease (2018) (26)
The Postnatal Development of AMPA Receptor Subunits in the Basal Ganglia of the Rat (1998) (26)
Retinoblastoma: sonographic findings with pathologic correlation in pediatric patients. (2000) (25)
The familial occurrence of Parkinson's disease. Lack of evidence for maternal inheritance. (1992) (25)
NEUROLOGICAL CONSEQUENCE OF INDUSTRIAL EXPOSURE TO 1-METHYL-4-PHENYL-1, 2, 3, 6-TETRAHYDROPYRIDINE (1985) (25)
High Throughput Automated Allele Frequency Estimation by Pyrosequencing (2008) (25)
Nigrostriatal Monoamine Oxidase A and B in Aging Squirrel Monkeys and C57BL/6 Mice (1997) (24)
MPTP: A Dopaminergic Neurotoxin (1997) (24)
Neurotoxicity of MPTP and MPP+ in vitro: characterization using specific cell lines (1988) (24)
Idiopathic Orthostatic Hypotension (1975) (24)
Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. (2006) (24)
Absence of elevated anti–&agr;-synuclein and anti-EBV latent membrane protein antibodies in PD (2002) (23)
Failure to find the alpha-synuclein gene missense mutation (G209A) in 100 patients with younger onset Parkinson's disease. (1998) (23)
Multiple causes of cerebrovascular events in children with tumors of the parasellar region (1998) (23)
Subtraction technique for contrast-enhanced MR images of musculoskeletal tumors. (1990) (22)
Role of Astrocytes in MPTP Metabolism and Toxicity a (1992) (22)
Mechanism of Accumulation of the 1‐methyl‐4‐Phenylpyridinium Species into Mouse Brain Synaptosomes (1991) (21)
1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. (1987) (21)
Journal of Parkinson's disease. (2011) (20)
Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys. (1993) (20)
Chronic Nicotine Treatment Increases nAChRs and Microglial Expression in Monkey Substantia Nigra After Nigrostriatal Damage (2009) (19)
Neuroimaging-detected late transient treatment-induced lesions in pediatric patients with brain tumors. (2005) (19)
LRRK2 p.Ile1371Val Mutation in a Case with Neuropathologically Confirmed Multi-System Atrophy. (2018) (18)
Therapies to Slow, Stop, or Reverse Parkinson’s Disease (2018) (18)
The Polymerization of Cyclohexene with Hydrogen Fluoride (1944) (18)
Medulloblastoma Metastatic to the Suprasellar Region at Diagnosis: A Report of Six Cases with Clinicopathologic Correlation (2002) (18)
Medium latency stretch reflexes in young-onset Parkinson's disease and MPTP-induced parkinsonism (1994) (17)
Candidate genes and Parkinson's disease: where to next? (1999) (17)
CT scanning in psychiatric inpatients: clinical yield. (1986) (17)
“Encephalomyeloneuritis” in the absence of cancer (1975) (17)
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced dopamine D2 receptor hypersensitivity in the mouse is transient. (1985) (17)
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa (2005) (17)
Modulating role of dopamine on anesthetic requirements (1990) (17)
Autoradiographic analysis of N-methyl-d-aspartate receptor binding in monkey brain: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Levodopa treatment (2000) (17)
Dextromethorphan protects against the neurotoxic effects ofp-chloroamphetamine in rats (1991) (17)
Selegiline and Parkinson’s disease (2000) (16)
Differential alterations in nicotinic receptor alpha6 and beta3 subunit messenger RNAs in monkey substantia nigra after nigrostriatal degeneration. (2000) (16)
Predicting Parkinson's disease. Discussion (1990) (16)
The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age (1989) (16)
Modulating role of dopamine on anesthetic requirements. (1988) (16)
Treatment of choroidal melanoma: MR imaging in the assessment of radioactive plaque position. (1990) (16)
Novel alpha-synuclein-immunoreactive proteins in brain samples from the Contursi kindred, Parkinson's, and Alzheimer's disease. (1998) (16)
MR imaging of growth recovery lines in fossil vertebrae. (1991) (15)
Ultrastructure of eosinophilic inclusion bodies in the amygdala-parahippocampal region of aged squirrel monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin (1995) (15)
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease (2021) (15)
MPTP‐Induced ATP Loss in Mouse Brain (1992) (15)
Parkin-proven disease (2003) (15)
Evaluation of the neurotoxic potential of N,N-dimethylamphetamine: an illicit analog of methamphetamine (1989) (15)
Chemical genomic profiling for identifying intracellular targets of toxicants producing Parkinson's disease. (2007) (14)
Quantitative MR imaging of children with sickle cell disease: Striking T1 elevation in the thalamus (1996) (14)
The biotransformation of MPTP and disposition of MPP+: the effects of aging. (1987) (14)
"Stelazine" versus "selegiline"--a hazard in prescription writing. (1990) (14)
Autoradiographic analysis of dopamine receptor-stimulated [35S]GTPγS binding in rat striatum (2000) (14)
Novel features in a patient homozygous for the L347P mutation in the PINK1 gene. (2007) (14)
The Impact of MPTP on Parkinson's Disease Research: Past, Present, and Future (2002) (13)
Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm (2018) (13)
Value of subtraction images in the detection of hemorrhagic brain lesions on contrast-enhanced MR images. (1991) (13)
Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. (1995) (12)
Aminophylline encephalopathy: a clinical, electroencephalographic, and neuropathological analysis. (1979) (12)
Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism. (1993) (12)
Neurobiology of Disease (2012) (12)
Does a long preclinical period occur in Parkinson's disease? (1991) (12)
The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging (1988) (12)
Infection with the Human Immunodeficiency Virus: Clinical Manifestations and Their Relationship to Immune (1987) (12)
Closer to Parkinson's disease: MPTP and the aging nervous system (1987) (10)
Unfavorable outcome of adrenal medullary transplant for Parkinson's disease (2004) (10)
Idiopathic orthostatic hypotension. Biochemical and pathologic observations in 2 cases. (1975) (10)
Infectious meningitis mimicking recurrent medulloblastoma on magnetic resonance imaging. Case report. (1999) (10)
CT scanning in psychiatric inpatients: II. Clinical data predicting scan results. (1988) (9)
ADRENAL MEDULLARY TRANSPLANT TO THE BRAIN FOR PARKINSONʼS DISEASE. NEUROPATHO-LOGY OF AN UNSUCCESSFUL CASE: 116 (1989) (9)
The neurophysiology and effect of deep brain stimulation in a patient with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism. (2009) (9)
Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants (2014) (8)
In Reply: Deprenyl and the Progression of Parkinson's Disease (1990) (7)
Evolution of nerve fiber degeneration in the striatum in the MPTP-treated squirrel monkey (1994) (7)
169 PATHOLOGY OF EXPERIMENTAL PARKINSONISM IN THE SQUIRREL MONKEY. SHORT TERM EFFECTS OF INTRAPERITONEAL ADMINISTRATION OF MPTP (1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE) (1984) (7)
Nonhypoxemic hazards of proionged myoclonus (1977) (7)
CRANIAL COMPUTED TOMOGRAPHY IN APHASIA (1976) (7)
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours (2018) (7)
Parkin gene variations and parkinsonism: Association does not imply causation (2007) (7)
Occupation and Risk of Parkinsonism (2016) (7)
Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation (2001) (7)
Diethyldithiocarbamate and disulfiram inhibit MPP+ and dopamine uptake by striatal synaptosomes. (1989) (7)
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration (2003) (6)
CT Scan in subcortical arteriosclerotic encephalopathy (1980) (6)
Effect of a gadodiamide contrast agent on the reliability of brain tissue T1 measurements. (1999) (6)
Safety and handling of MPTP (1985) (6)
Screening of ferritin light polypeptide 460–461InsA mutation in Parkinson's disease patients in North America (2002) (6)
Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on levels of glutamate and aspartate in the mouse brain (1994) (6)
Parkinson's disease is ready for precision medicine. (2016) (6)
Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease (1988) (6)
Deprenyl for the treatment of early Parkinson's disease. (1990) (6)
MPTP toxicity (2000) (5)
NEURONAL VULNERABILITY TO MPTP INJURY: ROLES OF AGING AND NEUROMELANIN (2001) (5)
Selegiline and Parkinson's disease. Protective and symptomatic considerations. (1990) (5)
P2.204 A randomized, double-blind, placebo-controlled, delayed start study to assess safty, tolerability and efflcacy of green tea polyphenols in Parkinson's disease (2009) (5)
Ketene Acetals. XIII. The Cyclic Trimerization of Ketene Diethylacetal by Hydrogen Fluoride: 1,1,3,3,5,5-Hexaethoxycyclohexane (1943) (5)
Loss-of-Function NUBPL Mutation May Link Parkinson's Disease to Recessive Complex I Deficiency (2020) (5)
R-(-)-deprenyl as a possible protective agent in Parkinson's disease. (1987) (5)
Imaging and therapeutics: the role of neuronal transport in the regional specificity of L-DOPA accumulation in brain. (2002) (5)
Occupation and Risk of Parkinsonism A Multicenter (2009) (5)
Parkinson's disease: current view. (1987) (5)
Quantitative white matter loss explains risks of young age for neurocognitive deficits in medulloblastoma survivors (2000) (5)
Nonhypoxemic hazards of prolonged myoclonus. (1977) (4)
99Tcm-HMPAO SPECT and magnetic resonance studies in L-asparaginase induced cerebrovascular accident. (1992) (4)
Contrast enhancement of pelvo-abdominal masses: the rim sign. (1974) (4)
Autoradiographic analysis of dopamine receptor-stimulated [(35)S]GTPgammaS binding in rat striatum. (2000) (4)
Discovery of 1H-Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors. (2022) (4)
Is PARKIN parkinsonism a cancer predisposition syndrome? (2015) (3)
ULTRASTRUCTURE OF NERVE CELL DEGENERATION IN THE SUBSTANTIA NIGRA IN EXPERIMENTAL MPTP-INDUCED PARKINSONISM IN THE MOUSE AND IN THE SQUIRREL MONKEY (1986) (3)
A Method of Utilizing Existing Information To Optimize Drilling Procedures (1966) (3)
LEWY BODIES AND AGING: 52 (1990) (3)
[Search for the cause of Parkinson's disease]. (1991) (2)
Curved reconstruction along the anterior optic pathway. (1998) (2)
Comparative genomic hybridization solves a 14‐year‐old PARKIN mystery (2015) (2)
Parkinsonism Induced By l-Methyl-4-Phenyl-l ,2,3,6-Tetrahydropyridine (MPTP): Implications for Treatment and the Pathogenesis of Parkinson's Disease (2004) (2)
Progress in Understanding the Mechanisms of Neuronal Dysfunction and Degeneration in Parkinson’s Disease (2007) (2)
THE HYPOTHALAMUS IN PARKINSON??S DISEASE: 102 (1976) (1)
The Emerging Entity of Pre‐Motor Parkinson's Disease (2011) (1)
Heart rate variability as a screening tool for Parkinson’s disease has age-dependent performance (P1.110) (2017) (1)
Large Scale Single Nucleotide Polymorphism Study of PD Susceptibility (2005) (1)
Patterns of Vulnerability of Mesostriatal Neurons (1990) (1)
P2.187 Relationship of neighboring tissue and gliosis to a-synuclein pathology in a fetal graft to treat Parkinson disease (2009) (1)
Scientific Program 20th Annual Meeting of the American Society of Pediatric Neurosurgeons (1996) (1)
169 The influence of histology on time to progression after irradiation for localized ependymoma in pediatric patients (1999) (1)
Current theories on the causeofParkinson's disease (1989) (1)
Heart Rate Variability in LRRK2 Parkinson’s Disease (S37.004) (2014) (1)
MPTP: Twenty Questions (1988) (1)
Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors. (2022) (1)
Erratum: Multisystem Lewy body disease and the other parkinsonian disorders (2016) (1)
Methods and compositions for reducing the side effects of therapeutic treatments (2008) (1)
168 Pediatric dorsally exophytic brain stem gliomas: Radiologic and clinicopathologic correlation (1999) (1)
Accelerating Research on Genes and Environment in Parkinson?s Disease (2005) (1)
Significance of small sharp spike waves in EEGs (1978) (1)
Xeroradiography. Its value in gas myelography. (1975) (1)
Consensus Statement Parkinson’s Disease and the Environment Collaborative on Health and the Environment and Parkinson's Action Network (CHE PAN) Conference June 26–28, 2007 (2008) (1)
Parkinson's Disease Risk Is Associated with Variants in Genes That Bind Bacterial Cell-Wall Peptidoglycan (P05.051) (2013) (1)
Spinal Teratomas versus Hamartomas (1998) (1)
Pesticide Exposure and Parkinsonʼs Disease (PD) in the Agricultural Health Study (AHS) (2009) (1)
Carboplatin and VP-16 in treatment of high stage medulloblastoma, pineoblastoma, and supratentorial primitive neuroectodermal tumors: A preliminary report (1992) (1)
Parkinson ' s disease . Current theories on the cause of (0)
Reply (2012) (0)
Validating Diagnostic and Screening Procedures for Pre-Motor Parkinson's Disease (2012) (0)
Parkinson Disease in Twins (2017) (0)
Heart Rate Variability in leucine-rich repeat kinase 2Associated Parkinsons Disease (2017) (0)
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours (2017) (0)
Parkinson’s disease associated with pure ATXN10 repeat expansion (2017) (0)
Optimizing Parkinson’s disease diagnosis: the role of a dual nuclear imaging algorithm (2018) (0)
Positioning platform for nonoblique total spine MR imaging. (1991) (0)
Genetic fine-mapping of the Iowan SNCA gene triplication in a patient with Parkinson’s disease (2018) (0)
Neuroimaging characteristics of progressive optic pathway tumors: Pediatric oncology group study (1994) (0)
( (cid:49) )MK-801 Does Not Prevent MPTP-Induced Loss of Nigral Neurons in Mice 1 (1997) (0)
The neurophysiology and effect of deep brain stimulation in a human with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -induced parkinsonism (2010) (0)
Towards a Strategy for Preventing Parkinson’s Disease (1990) (0)
PARK1 and α-Synuclein (2003) (0)
Genome Editing of α-Synuclein in iPSCs from a Donor with Multiple System Atrophy (2013) (0)
Risk of Parkinson's Disease (PD) Associated with the Herbicide Paraquat Is Attenuated by High Dietary Intake of Polyunsaturated Fatty Acids (PUFAs) (S42.004) (2012) (0)
IMMUNOSTAINING OF LEWY BODIES WITH ANTIBODY TO SYNAPTOPHYSIN (1998) (0)
2189 Retrospective review of pediatric oligodendrogliomas (1997) (0)
Past, Present, Future and Critical Issues for Psychiatric-Mental Health Nurses (2011) (0)
Composition for the reduction of side-effects of dopaminergic agents (2008) (0)
ALTERATIONS IN THE ROUGH ENDOPLASMIC RETICU-LUM IN MPTP-INDUCED SUBSTANTIA NIGRA DEGENERATION IN THE SQUIRREL MONKEY (1993) (0)
Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders (2008) (0)
Reply (2002) (0)
Paraquat Use Modifies the Association of Head Injury and Parkinson's Disease (PD) (S42.003) (2012) (0)
PARKINSONISM SECONDARY TO PETROLEUM EXPOSURE. AUTHORS' REPLY (1995) (0)
Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like (2008) (0)
Novel electrophysiological phenotype and ion channel composition in iPS neurons from LRRK2 Parkinson's patients (2013) (0)
Risks o f Y oung A ge f or S elected N eurocognitive D eficits i n Medulloblastoma A re A ssociated W ith W hite M atter L oss (2001) (0)
Reply (2000) (0)
Predicting Parkinson's disease (1990) (0)
Subtle volume differences in brain parenchyma of children surviving medulloblastoma (1998) (0)
Protective and preventive therapeutic strategies: monoamine oxidase inhibitors. (1992) (0)
Parkinsonian tremor (1993) (0)
Mitochondrial bioenergetics in stem cell models of neurodegeneration (2012) (0)
NEUROPATHOLOGY OF HUMAN MPTP-INDUCED PARKINSONISM (1997) (0)
PD in a petri-dish: overcoming a major bottleneck in modeling Parkinson's disease (2011) (0)
Pediatric craniopharyngiomas: analysis of functional outcome by extent of surgery and radiotherapy (1992) (0)
Interdiscipline Design Coordination Facilitated by CADD (1994) (0)
ENVIRONMENTAL PERSPECTIVES ENVIRONMENTAL PERSPECTIVES (2008) (0)
Protective Glove Use and Workplace Hygiene Practices Modify Associations between Pesticides and Parkinson's Disease (2014) (0)
Clinical and neuropathological features: session III summary and research needs. (2001) (0)
Abstracts of the 15th Annual Meeting of the American Society of Neuroradiology (2004) (0)
High efficiency of neural induction in Parkinson's disease-specific induced pluripotent stem cells (2011) (0)
Journal of Parkinson's Disease--an excellent first year and a new sister. (2012) (0)

This paper list is powered by the following services:

Other Resources About William Langston

What Schools Are Affiliated With William Langston?

William Langston is affiliated with the following schools: